🔗 Share this article

While America proceeds with unprecedented adjustments to its vaccination schedules, one figure appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus vaccinations in the global health crisis and has concentrated on potential deaths after COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Public health authorities planned to reveal sweeping changes to the pediatric immunization program in December, bringing the US with the Danish vaccine program, it is understood – a major change that would place the US at odds with much of the global community with little proof for public health gain. The announcement has been pushed back until the new year.

In place of the director of the vaccine center, Dr. Høeg is listed to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.

A New Direction at the Agency

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific pediatric immunization guidelines in the US to become more like Denmark's approach, a society with universal health coverage and a population approximately the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – traditionally the domain of Prasad, chief of the FDA’s CBER – rather than medication approval.

Concerns Over Background

The appointee has no apparent background in medication creation, oversight or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She appears not to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Past heads of the center would “understand legal statutes and the research of drug development”, said Dr. Janet Woodcock. “Clearly, she lacks the kind of background that prior appointees who ran CBER have had.”

This division has an enormous workload at the agency, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the off-patent medication office clears numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these have to be looked after,” Dr. Woodcock noted. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a significant administrative element to the position, which oversees more than 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” the former official said.

Agency Reaction and Contentious Policies

Regarding questions about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among FDA leaders on vaccines, a spokesperson said that the “questions rely on flawed presumptions”.

“Her resume matches the functions of her job,” the official stated, citing the time Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's new expedited review system, a disputed expedited drug-approval program that reportedly troubled her predecessors. “By what process are these drugs being chosen for this voucher program? Who makes the calls?” Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards laxer regulations of pharmaceuticals, except for immunizations.”

Established Past Work on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, past, some experts observe. She released a research paper using non-validated public submissions to estimate the incidence of myocarditis after Covid immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the incoming administration encompassed changing guidelines for novel immunizations and discontinuing “optional” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has allegedly floated the idea of preventing adolescent males from receiving Covid vaccinations.

“She is an complete true believer who begins with her preconceived notions and tailors the evidence to accommodate the evidence in a very deceptive, untruthful fashion,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg joined other skeptics, {like|